Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

著者: Sébastien Anguille, Ann L. Van de Velde, Evelien Smits, Viggo Van Tendeloo, Gunnar Juliusson, Nathalie Cools, Griet Nijs, Barbara Stein, Eva Lion, Ann Van Driessche, Irma Vandenbosch, Anke Verlinden, Alain Gadisseur, Wilfried Schroyens, L. Muylle, Katrien Vermeulen, Marie‐Berthe Maes, Kathleen Deiteren, Ronald Malfait, Emma Gostick, Martin Lammens, Marie M. Couttenye, Philippe G. Jorens, Herman Goossens, David A. Price, Kristin Ladell, Yoshitaka Oka, Fumihiro Fujiki, Yusuke Oji, Haruo Sugiyama, Zwi Berneman - Blood 2017 被引用: 233

Key Points WT1 mRNA-electroporated DCs can prevent or delay relapse in 43% of patients with AML in remission after chemotherapy. OS compares favorably with the new survival data from the Swedish Acute Leukemia Registry and correlates with molecular and WT1-specific CD8+ T-cell responses.